Viewing Study NCT00608868


Ignite Creation Date: 2025-12-24 @ 6:28 PM
Ignite Modification Date: 2025-12-28 @ 12:04 AM
Study NCT ID: NCT00608868
Status: COMPLETED
Last Update Posted: 2012-09-28
First Post: 2008-01-23
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
Sponsor: AstraZeneca
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non Small Cell Lung Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Carcinoma View
None Non Small Cell Lung View
None EGFR mutation View
None Gefitinib View